drugset / Trial / NCT04298060
DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
Timeline
- Start
- 2020-07
- Primary completion
- 2021-03
- Completion
- 2022-09